血浆甲基乙二醛水平与严重肢体缺血患者截肢和死亡相关
本研究在160例无选项严重肢体缺血患者中检测基线血浆甲基乙二醛(MGO)等指标,随访5年记录主要不良结局。发现较高血浆MGO水平与更多不良结局和截肢相关,MGO衍生的AGE Nε-羧乙基赖氨酸亦与不良结局和截肢相关,提示MGO可能为SLI预后标志。
要点
- 血浆MGO每升高1个标准差,不良结局相对风险1.44,截肢风险1.55。
- MGO衍生的AGE Nε-羧乙基赖氨酸与不良结局和截肢相关。
- d-乳酸与不良结局无关,MGO或为SLI干预靶点。
核心结论
- 血浆MGO水平与严重肢体缺血患者不良结局相关,未来需研究靶向MGO治疗是否改善结局。
研究设计与样本
- 在160例无选项严重肢体缺血患者中,用超高效液相色谱-串联质谱法检测基线血浆MGO、游离AGEs和d-乳酸,随访5年记录主要不良结局。
主要发现
- 血浆MGO每升高1个标准差,不良结局相对风险1.44(95%CI 1.11-1.86),截肢相对风险1.55(95%CI 1.13-2.21),死亡相对风险1.28(95%CI 0.93-1.77)。
- MGO衍生的AGE Nε-羧乙基赖氨酸每升高1个标准差,不良结局相对风险1.46(95%CI 1.00-2.15),截肢相对风险1.71(95%CI 1.04-2.79)。
- d-乳酸与不良结局无关;较高血浆MGO水平与更多炎症、白细胞增多和祖细胞减少相关。
临床怎么用
- 血浆MGO水平或可用于严重肢体缺血患者截肢和死亡风险分层。
局限性
- 研究为观察性设计,不能确定MGO与不良结局的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diabetes is a risk factor for severe limb ischemia (SLI), a condition associated with high mortality, morbidity, and limb loss. The reactive glucose-derived dicarbonyl methylglyoxal (MGO) is a major precursor for advanced glycation end products (AGEs) and a potential driver of cardiovascular disease. We investigated whether plasma MGO levels are associated with poor outcomes in SLI. RESEARCH DESIGN AND METHODS: We measured plasma levels of MGO, free AGEs, and d-lactate, the detoxification end product of MGO, with ultraperformance liquid chromatography-tandem mass spectrometry at baseline in 160 patients (64.8 ± 13.3 years, 67.5% male, 37.5% with diabetes) with no-option SLI and recorded major adverse outcomes (n = 86, comprising n = 53 deaths and n = 49 amputations [first event counted]) over the 5-year follow-up. Data were analyzed with linear or Cox regression, after Ln-transformation of the independent variables, adjusted for sex, age, trial arm, diabetes, estimated glomerular filtration rate, systolic blood pressure, cholesterol levels, and BMI. Associations are reported per 1 SD plasma marker. RESULTS: Higher plasma MGO levels were associated with more adverse outcomes (relative risk 1.44; 95% CI 1.11-1.86) and amputations separately (1.55; 1.13-2.21). We observed a similar but weaker trend for mortality (1.28; 0.93-1.77). The MGO-derived AGE Nε-(carboxyethyl)lysine was also associated with more adverse outcomes (1.46; 1.00-2.15) and amputations (1.71; 1.04-2.79). d-Lactate was not associated with adverse incident outcomes. Higher plasma MGO levels were also associated with more inflammation and white blood cells and fewer progenitor cells. CONCLUSIONS: Plasma MGO levels are associated with adverse outcomes in SLI. Future studies should investigate whether MGO-targeting therapies improve outcomes in SLI.
引用
- Hanssen NMJ, Teraa M, Scheijen JLJM, et al. Plasma Methylglyoxal Levels Are Associated With Amputations and Mortality in Severe Limb Ischemia Patients With and Without Diabetes. Diabetes Care. 2020. PMID: 33144352. doi:10.2337/dc20-0581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。